Under the US$475 million (THB16.46 billion) acquisition deal, Innobic became the largest shareholder of Lotus Pharmaceutical with a 37 per cent stake, and of Adalvo with a 60 per cent stake. The acquisition aims to increase the strength of both Lotus Pharmaceutical and Adalvo as world leaders in pharmaceutical and patent trading industries, as well as increase Thailand’s accessibility to drugs of international standard.
Aztiq Pharma Partners and Innobic (Asia) Company have acquired the complete stake in Alvogen Emerging Market Holdings (AEMH) from its current shareholders for $500m.
A consortium led by Icelandic pharmaceutical investment fund Aztiq and Thailand-based life sciences company Innobic has agreed to acquire all shares of Alvogen Emerging Market Holdings (AEMH) from its current stakeholders for $475m.
Aztiq Pharma Partners, a private equity fund led by Róbert Wessman, today announced that it has completed a US$100 million financing to purchase a newly issued share equity in Alvogen US. Morgan Stanley led the financing, which was subscribed by international institutional investors.